Update of the role of Lp(a) in determination of the CV risk and methods of influencing it

1. Berg K. A new serum type system in man: the Lp sytem. Acta Pathol Microbial Scand 1963; 59: 369–382.

2. Morrisett JD, Guyton JR, Gaubatz JW et al. Lipoprotein (a): structure, metabolism and epidemiology. In: Plasma lipoproteins. Gotto AM. (ed). New Comprehensive Biochemistry. Elsevier Sci Publ 1987; 14: 129–152. doi: 10.1016/ S0167-7306(08)60198-2.

3. Seegers W, Hirschhorn K, Burnett L et al. Double beta-lipoprotein: a new genetic variant in man. Science 1965; 149(3681): 303–304. doi: 10.1126/ science.149.3681.303.

4. Dahlén G, Ericson C, Furberg C et al. Studies on an extra pre-beta lipoprotein fraction. Acta Med Scand Suppl 1972; 531: 1–29.

5. Sines J, Rothnagel R, van Heel M et al. Electron cryo­mycroscopy and digital image processing of Lp(a). Chem Phys Lipids 1994; 67/ 68: 81–89.

6. Marcovina SM, Morrisett JD. Structure and metabolism of lipoprotein (a). Curr Opin Lipidol 1995; 6(3): 136–145.

7. Koschinsky ML, Cote GP, Gabel B et al. Identification of the cystein residue in apolipoprotein(a) that mediates extracellular couping with apolipoprotein B-100. J Bioch Chem 1993; 268(26): 1819–19825.

8. Hixson JE, Britten ML, Manis GS et al. Apolipoprotein(a) glycoprotein isoform result from size differences in Apo(a) mRNA in baboons. J Biol Chem 1989; 264(11): 6013–6016.

9. Morrisett JD, Gaubatz JW, Knapp RD et al. Structural properties of apo (a): a major apoprotein of human lipoprotein (a). In: Lipoprotein (a). Scanu AM (ed). San Diego: Academic Press Ic. 1990: 53–74.

10. Lackner C, Cohen JC, Hobs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2(7): 933–940. doi: 10.1093/ hmg/ 2.7.933.

11. Eaton DL, Fless GM, Kohr W jet al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84(10): 3224–3228. doi: 10.1073/ pnas.84.10.3224.

12. White AL, Hixson JE, Rainwater DL et al. Molecular basis for „null“ lipoprotein(a) phenotyps and influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem 1994; 269(12): 9060–9066.

13. Lackner C, Boerwinkle E, Leffert C et al. Molecular basis of apolipoprotein(a) isoform size heterogenity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87(6): 2153–2161. doi: 10.1172/ JCI115248.

14. Boerwinkle E. Genetics of plasma lipoprotein (a) concentrations. Curr Opin Lipidology 1992; 3: 128–136.

15. Krempler F, Kostner GM, Bolzano K et al. Turn­over of lipoprotein (a) in man. J Clin Invest 1980; 62(6): 1483–1490. doi: 10.1172/ JCI109813.

16. Kraft HG, Menzel HJ, Hoppichler F et al. Changes of genetics apolipoprotein phenotypes caused by liver transplantation. Implication for apolipoprotein synthesis. J Clin Invest 1989; 83(1): 137–142. doi: 10.1172/ JCI113849.

17. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999; 10(3): 225–236.

18. Argraves KM, Kozarsky KF, Fallon JT et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100(9): 2170–2181. doi: 10.1172/ JCI119753.

19. Parra HJ, Mezdour H, Cachera C et al. Lp(a) lipoprotein in patients with chronical renal failure treated by hemodialysis. Clin Chem 1987; 33(5): 721.

20. Higazi AA, Lavi E, Bdeir K et al. Defensin stimulated the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 1997; 89(12): 4290–4298.

21. Philips ML, Lembertas AV, Schumaker VN et al. Physical properties of recombinant apo(a) and its association with LDL to form an Lp(a)-like complex. Biochemistry 1993; 32(14): 3722–3728.

22. Yano Y, Shimokawa K, Okada Y et al. Immunolocalizacion of lp(a) in wounded tissues. J Histochem Cytochem 1997; 45(4): 559–568. doi: 10.1177/ 002215549704500408.

23. Baggio G, Donazzan S, Monti D et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factor. FASEB J
1998; 12(6): 433–437. doi: 10.1096/ fasebj.12.6.433.

24. Marcovina SM, Albers JJ, Wijsman E et al. Differences in Lp(a) concentrations and apo(a) polymorphysm between black a white Americans. J Lipid Res 1996; 37(12): 2569–2585.

25. Kojima S, Harpel PC, Rifkin DB et al. Lipoprotein (a) inhibits the generation of trasforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113(6): 1439–1445. doi: 10.1083/ jcb.113.6.1439.

26. Heberland ME, Fless GM, Scanu AM et al. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocytemacrophages. J Biol Chem 1992; 267(6): 4143–4151.

27. Nachman RL. Thrombosis and atherogenesis: molecular connections. Blood 1992; 79(8): 1897–1906.

28. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med 1996; 47: 423–442. doi: 10.1146/ annurev.med.47.1.423.

29. Cooke JP. The pathophysiology of periferal arterial disease: rational targets for drug intervention. Vasc Med 1997; 2: 227–230.

30. Seman LJ, DeLuca C, Jenner JL et al. Lipoprotein(a)-cholestrol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999; 45(7): 1039–1046.

31. Milionis HJ, Winder AF, Mikhailidis DP et al. Lipoprotein(a) and stroke. J Clin Pathol 2000; 53(7): 487–496. doi: 10.1136/ jcp.53.7.487.

32. Miner SE, Hegele RA, Sparkes J et al. Homocystein, lipoproteine(a) levels and restenosis after PTCA: a prospective study. Am Heart J 2000; 140:
272–278.

33. von Depka M, Nowak-Göttl U, Eisert R et al. In­creased lipoprotein (a) levels as an indipendent risk factor for venous tromboembolism. Blood 2000; 96(10): 3364–3368.

34. Angelin B. Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 1997; 8(6): 337–341.

35. Seed M, O’Connor B, Perombelon N et al. The effect of nicotin acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis 1993; 101(1): 61–68.

36. Ramharack R, Spahi MA, Hicks GW et al. Gemfibrozil significantly lowers cynomolgus monkey plasma lipoprotein (a)-protein and liver apolipoprotein (a) mRNA levels. J Lipid Res 1995; 36(6): 1294–1304.

37. Galetta F, Sampietro T, Basta G et al. Effects of simvastatin on blood levels of lipoprotein (a). Minerva Med 1995; 86(7–8): 299–303.

38. Bambauer R, Schiel R, Keller HE et al. Low-density lipoprotein apheresis in the treatment of two patients with coronary heart disease and extremely elevated lipoprotein (a) levels.. Artif Organs 1996; 20(4): 340–343.

39. Henriksson P, Angelin B, Berglund L. Hormonal regulatulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992; 89(4): 1166–1171. doi: 10.1172/ JCI115699.

40. Navarese EP, Kolodziejczak M, Schulze V et al. Effects of proprotein convertase subtilisin/ kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015; 163(1): 40–51. doi: 10.7326/ M14-2957.

41. Gaudet D, Watts GF, Robinson JG et al. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the Phase 3 ODYSSEY Program). Am J Cardiol 2017; 119(1): 40–46. doi: 10.1016/ j.amjcard.2016.09.010.

42. O'Donoghue ML, Fazio S, Giugliano RP et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019; 139(12): 1483–1492. doi: 10.1161/ CIRCULATIONAHA.118.037184.

43. Viney NJ, van Capelleveen JC, Geary RS et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388(10057): 2239–2253. doi: 10.1016/ S0140-6736(16)31009-1.

44. Catapano AL, Graham I, De Backer G et al. 2016 ESC/ EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058. doi: 10.1093/ eurheartj/ ehw272.